West Clinic — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$57,378	1
2022	Research	$12,730	12
2021	Research	$7,593	5
2020	Research	$29,252	14
2019	Research	$24,800	16

Breakdown

Who paid Research payments · program years 2019–2025

Mirati Therapeutics, Inc. $57,378 1 payment
Novartis Pharmaceuticals Corporation $46,617 9 payments
TG Therapeutics, Inc. $15,400 15 payments
E.R. Squibb & Sons, L.L.C. $11,200 1 payment
Pfizer Inc. $945 21 payments
Merck Sharp & Dohme Corporation $213 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation $57,378 1 payment
A Phase Ib II Open Label Multicenter Study of McS110 in Combination With Pdr001 in Patients With Advanced Malignancies $23,285 3 payments
Extension Trial of Ublituximab and Umbralisib (TGR-1202) in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials $14,400 14 payments
Altto A Randomized Multicentre Open Label Phase III Study of Adjuvant Lapatinib Trastuzumab Their Sequence and Their Combination in Patients With Her2 and Or Erbb2 Positive Primary Breast Cancer $12,977 3 payments
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer $11,200 1 payment
A Randomized Double Blind Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib As Adjuvant Therapy for Subjects With Localized Or Locally Advanced RCC Following Nephrectomy $8,546 2 payments
A Phase III Open Label Randomized Multicenter Trial of Ofatumumab Maintenance Treatment Versus No Further Treatment in Subjects With Relapsed Chronic Lymphocytic Leukemia CLL Who Have Responded to Induction Therapy $1,808 1 payment
(GENUINE) Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) $1,000 1 payment
A Randomized Multicenter Doubleblind Phase 3 Study of Pd0332991 Oral CDK 46 Inhibitor Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women With Er Her2 Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment for Advanced Disease $945 21 payments
A Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab MK 3475 with or without Lenvatinib E7080,MK 7902 as First line Intervention in Participants with Metastatic Nonsquamous Non small Cell Lung Cancer LEAP 006 $213 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.